Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review.

ABSTRACT:

Background

Several tyrosine kinase receptors inhibitors (TKIs) have demonstrated antiproliferative effects in well-differentiated neuroendocrine tumors (NETs). We aimed to summarize and appraise the current evidence of the efficacy of TKIs in patients with different types of NETs.

Methods

We performed a systematic review of clinical trials of TKIs in patients with advanced gastroenteropancreatic or lung NETs (PROSPERO registration number: CRD42024507379). Population characteristics, efficacy, and safety results were summarized by type of NET.

Results

Twenty-eight studies were eligible, totaling 2284 patients. While sunitinib remains the only Food and Drug Administration-approved TKI in patients with NETs (for patients with pancreatic well-differentiated NETs), recent

SUBMITTER: Taboada RG 

PROVIDER: S-EPMC11483706 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature